Tokyo (SCCIJ) – The Swiss pharmaceutical giant Roche is teaming up with Ibex Medical Analytics and Amazon Web Services in the field of artificial intelligence. The goal is to help pathology labs diagnose cancer faster and more efficiently. Roche describes the partnership as a step forward in personalized medicine.
Roche headquartered in Basel collaborates with Ibex Medical Analytics for AI-powered digital pathology (© Roche).
Digital pathology
The collaboration of Roche, Ibex, and Amazon Web Services enables pathology laboratories to access Ibex’s AI-powered decision support tools to help clinicians in breast and prostate cancer diagnosis through the digital pathology software platform Navify.
Digital pathology refers to the digitalization of the traditional pathology workflow starting from slide scanning to visualization to analysis. Digital pathology is transforming traditional histopathology by improving efficiency, and depth of analysis, and providing an opportunity for collaboration in pathology workflows. The integrated AI-based tools can be applied to help enhance clinical decision support, improve productivity, and shorten turnaround time in pathology laboratories.
“This exciting collaboration brings powerful AI solutions to pathology labs,” said Michael Rivers, Lifecycle Leader for Roche Digital Pathology. “Using the Navify Digital Pathology platform pathologists can securely access third-party AI-powered technology alongside Roche’s growing menu of AI-based image analysis tools in an efficient clinical workflow.”
New workflows
Ibex’s AI algorithms help clinicians in the diagnosis of breast and prostate biopsies and provide efficient, accurate, and timely cancer diagnosis, support case prioritization, determine the cancer grading and subtype, and identify important non-cancerous features. All of this detailed diagnosis information is displayed seamlessly in the Navify Digital Pathology solution.
The Ibex algorithms are used at laboratories and hospitals worldwide, and help clinicians improve patient care as demonstrated by multiple clinical studies performed in the United States and Europe. These algorithms are currently for research use only, not for use in diagnostic procedures, in the United States, and CE-Marked for in vitro diagnostics use in Europe for breast and prostate cancer detection in multiple workflows.
“Our collaboration with Roche is driving new AI-powered workflows that help pathologists and laboratories realize the full potential of going digital,” said Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics. “The next phase in the evolution of digital pathology is open platforms that enable technology providers to join forces and offer integrated software solutions that improve lab efficiency, biopsy review and ultimately the quality of patient care.”
Roche’s solution and Ibex’s algorithms operate on the highly secure and scalable Amazon Web Services. This cloud infrastructure provides customers with flexibility, security, computing capacity, responsiveness, and confidence to accelerate the adoption of digital pathology and AI.
Text: Roche Diagnostics (Editing by SCCIJ)
